 WILMINGTON, Del., Dec. 16, 2020 GLOBE NEWSWIRE -- Rigrodsky Long, P.A. announces that it is investigating Prevail Therapeutics Inc. Prevail NASDAQ GS: PRVL regarding possible breaches of fiduciary duties and other violations of law related to Prevails agreement to be acquired by Eli Lilly and Company NYSE: LLY. Under the terms of the agreement, Prevails shareholders will receive 22.50 in cash per share, plus one contingent value right, which represents the right to receive a contingent payment of up to 4.00 per share. 